CMS Narrows Medicare Coverage for Skin Substitutes to 18 Products, Impacting Wound Care Market
核心洞察
The Centers for Medicare & Medicaid Services (搜索) (CMS) has dramatically reduced Medicare coverage for skin substitutes from 340 products to just 18 evidence-based products for treating diabetic foot and venous leg ulcers (搜索), effective January 1, 2026.
All covered products will be reimbursed at a standardized rate of $127/cm², eliminating pricing-driven treatment decisions and allowing clinicians to focus on selecting the most appropriate therapy for each patient.
An additional 154 products have been placed in a discretionary category with 12-month status quo period, remaining eligible for case-by-case payment at Medicare Administrative Contractors' discretion.
The Centers for Medicare & Medicaid Services (搜索) (CMS) has announced sweeping changes to Medicare coverage for skin substitutes, dramatically reducing the number of covered products from 340 to just 18 evidence-based options for treating diabetic foot ulcers (搜索) and venous leg ulcers (搜索). The updated Local Coverage Determinations (LCDs), effective January 1, 2026, represent a major shift toward evidence-based reimbursement in the wound care market.
Standardized Reimbursement Framework
Under the new policy, all 18 covered products will be reimbursed at a standardized rate of $127/cm², as previously announced by CMS on October 31, 2025. This unified payment approach is designed to reduce variability across sites of care, eliminate pricing-driven treatment decisions, and allow clinicians to focus on selecting the most appropriate therapy for each patient.
Notably, CMS indicates that seven of the 18 covered products are currently priced at or below the standardized $127/cm² rate, reinforcing CMS's emphasis on predictable, efficient reimbursement aligned with clinical value.
Three-Tier Coverage System
CMS has established three distinct categories for skin substitute products:
Covered Products (18 total): These evidence-based products receive guaranteed Medicare coverage and standardized reimbursement for diabetic foot and venous leg ulcers (搜索).
Discretionary MAC Category (154 products): Products in this category remain eligible for payment at Medicare Administrative Contractors' (MACs) discretion on a case-by-case patient basis, subject to detailed documentation of medical necessity. These products will be reimbursed at the same standardized rate of $127/cm² during a 12-month status quo period.
Non-Covered Category: Products that will not receive Medicare reimbursement under the new LCDs.
Industry Impact and Company Responses
Several companies have secured positions among the covered products. Kerecis (搜索), which develops fish-skin derived medical devices, has two products included in the covered category: MariGen (搜索)® and Shield (搜索)®. "Being two of only 18 covered products nationwide reflects the strength of our clinical evidence and makes Kerecis an easy partner for providers," said Fertram Sigurjonsson, Coloplast EVP of Wound & Tissue Repair and founder and CEO of Kerecis.
BioStem Technologies announced that its products VENDAJE® and VENDAJE AC (搜索)® have been placed in the 12-month status quo category. "We expect the Status Quo designation to provide uninterrupted payment for VENDAJE and VENDAJE AC in DFU and VLU applications throughout 2026," said Jason Matuszewski, Chief Executive Officer and Chairman of BioStem Technologies.
Limited Scope of Changes
Importantly, the final LCDs apply exclusively to diabetic foot ulcers (搜索) and venous leg ulcers (搜索). Coverage for other wound types remains unaffected, including pressure ulcers (搜索), which comprise 41% of the chronic wound market. This limitation preserves existing billing processes and provider flexibility for non-DFU/VLU patient populations.
Future Review Process
At the end of the 12-month period, MACs will conduct a formal evidence review of products in the discretionary category and consider moving some to the covered products list. Companies must submit additional evidence by December 31, 2026, with updated determinations expected in early 2027.
BioStem Technologies has indicated it provided CMS and MACs with new clinical data prior to the November evidence submission deadline, including results from a DFU study demonstrating "statistically significant superiority over the standard of care." The company plans to continue dialogue with CMS and MACs regarding its clinical trial findings and ongoing VLU clinical trial progress.
The standardized reimbursement rate, combined with aligned national LCDs and site-of-service neutrality under the CY 2026 rules, creates a more predictable environment for clinicians and healthcare systems, allowing providers to plan wound care pathways with greater confidence and reduced administrative burden.